Cover Image
Market Research Report

COVID-19 Global Diagnostic Demand Outlook by Country. Assay Volume Quarterly Outlook to December 2021 Separately for Molecular and Serology. Updated to Include Q1 & Q2 2020 Actuals Data

Published by Howe Sound Research Product code 954976
Published Content info 218 Pages
Delivery time: 1-2 business days
Price
Back to Top
COVID-19 Global Diagnostic Demand Outlook by Country. Assay Volume Quarterly Outlook to December 2021 Separately for Molecular and Serology. Updated to Include Q1 & Q2 2020 Actuals Data
Published: August 24, 2020 Content info: 218 Pages
Description

OVERVIEW:

Can diagnostics stop an epidemic? Rapid diagnostics is key to epidemic management. But the demand is staggering. Will it stagger the diagnostics industry? This report looks at the assay volume demands by country looking out 6 quarters to the end of 2021. We look at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario. A breakout of Molecular and Serology is also included. As always, our analysts are available to breakout separate numbers to meet your needs and work with your assumptions.

Our forecasts are based on the WHO Health Security Index with specific assumptions about the effectiveness of distancing measures and the impact of health system overload on different countries. These create varying timelines of demand.

All report data is available in Excel format on request.

Make projections with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School
Table of Contents

Table of Contents

i. COVID-19. Strategic Situation Analysis

ii. COVID-19. Guidance for Executives

iii. COVID-19. Guidance for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What are Pandemics?
  • 1.2. The Role of Zoonosis
  • 1.3. Market Definition
    • 1.3.1. Assay Volumes.
    • 1.3.2. Healthcare Systems Demand
    • 1.3.3. Molecular & Serology
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. Historical Perspective on Pandemics
    • 1.5.1. HIV/AIDS PANDEMIC 2005-2012
    • 1.5.2. FLU PANDEMIC 1968
    • 1.5.3. ASIAN FLU 1956-1958
    • 1.5.4. SPANISH FLU 1918
    • 1.5.5. SIXTH CHOLERA PANDEMIC 1910-1911
    • 1.5.6. FLU PANDEMIC 1889-1890
    • 1.5.7. THE BLACK DEATH 1346-1353

2. The Pandemic Overview

  • 2.1. What is a Virus?
    • 2.1.1. Is a Virus Alive?
    • 2.1.2. Viral Structure
    • 2.1.3. The Viral Genome
    • 2.1.4. Viral Mutation
  • 2.2. The Coronavirus
    • 2.2.1. Severe acute respiratory syndrome (SARS)
    • 2.2.2. Middle East respiratory syndrome (MERS)
    • 2.2.3. COVID-19. The SARS CoV 2 Virus
      • 2.2.3.1. Signs and symptoms
      • 2.2.3.2. Transmission
      • 2.2.3.3. Diagnosis
      • 2.2.3.4. Prevention
      • 2.2.3.5. Management
      • 2.2.3.6. Prognosis
      • 2.2.3.7. A Note on Global Statistics Reporting
  • 2.3. Pandemic Diagnostics
    • 2.3.1. Risk Management-Spark and Spread
    • 2.3.2. Dx Technology-Nucleic Acid Based
    • 2.3.3. Dx Technology - Immunoassay
    • 2.3.4. Time to Market and Preparedness Issues
    • 2.3.5. Saliva Direct Test
      • 2.3.5.1. Research Abstract
      • 2.3.5.2. FDA Statement on Saliva Direct Test
      • 2.3.5.3. Impact of Saliva Direct on Forecasts and Cannibalization

3. Infection/Hospitalization Projections by Country by Quarter. All Case Secenarios

  • 3.1. Scenarios Overview
    • 3.1.1. WHO Global Health Security Index
    • 3.1.2. Pandemic Progression Outlook Methodology
  • 3.2. Scenario 1. Best Case
  • 3.3. Scenario 2. Expected Case
  • 3.4. Scenario 3. Worst Case

4. Diagnostic Company Profiles

  • 1drop
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Advanced Biological Laboratories
  • Akkoni Biosystems
  • Altona Diagnostics
  • Alveo Technologies
  • Applied BioCode
  • Applied DNA Sciences
  • Anatolia Geneworks
  • Assurance Scientific Laboratories
  • Aus Diagnostics
  • Autobio Diagnostics
  • BD Diagnostics
  • BGI Genomics Co. Ltd
  • Biocartis
  • Biodesix
  • BioFire Diagnostics
  • Biolidics
  • bioMérieux
  • Bioneer
  • Bio-Rad Laboratories
  • BioReference Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cerstest Biotec
  • Chembio Diagnostics
  • Color Genomics
  • Credo Diagnostics Biomedical
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Enzo Life Sciences, Inc.
  • Exact Sciences
  • Expedeon
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • GenePOC Diagnostics
  • Genetic Signatures
  • Genetron
  • GenMark Dx
  • Gold Standard Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Laboratory Corporation of America
  • Lexagene
  • Luminex
  • Mayo Clinic Laboratories
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Novacyt
  • Orig3n
  • Ortho Clinical Diagnostics
  • Oxford Nanopore
  • Panagene
  • PerkinElmer
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quest Diagnostics
  • Quidel
  • Randox Laboratories
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • SD Biosensor
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veredus Labs
  • Vircell
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

5. Healthcare Systems Dx Demand Outlook

  • 5.1. Healthcare System Demand by Country-Best Case
    • 5.1.1. Table-Healthcare Dx Total Demand by Country-Best Case
    • 5.1.3. Chart-Global Healthcare Dx Total Demand by Quarter-Best Case
  • 5.2. Healthcare System Demand by Country-Expected Case
    • 5.2.1. Table-Healthcare Dx Total Demand by Country-Expected Case
    • 5.2.3. Chart-Global Healthcare Dx Total Demand by Quarter-Expected Case
  • 5.3. Healthcare System Demand by Country-Worst Case
    • 5.3.1. Table-Healthcare Dx Total Demand by Country-Worst Case
    • 5.3.3. Chart-Global Healthcare Dx Total Demand by Quarter-Worst Case

6. Molecular/Serology Dx Demand Outlook

  • 6.1. Molecular/Serology Demand by Country-Best Case
    • 6.1.1. Table-Molecular Dx Total Demand by Country-Best Case
    • 6.1.2. Table-Serology Dx Total Demand by Country-Best Case
    • 6.1.3. Chart-Global Molecular Dx Total Demand by Quarter-Best Case
    • 6.1.4. Chart-Global Serology Dx Total Demand by Quarter-Best Case
  • 6.2. Molecular/Serology Demand by Country-Expected Case
    • 6.2.1. Table-Molecular Dx Total Demand by Country-Expected Case
    • 6.2.2. Table-Serology Dx Total Demand by Country-Expected Case
    • 6.2.3. Chart-Global Molecular Dx Total Demand by Quarter-Expected Case
    • 6.2.4. Chart-Global Serology Dx Total Demand by Quarter-Expected Case
  • 6.3. Molecular/Serology Demand by Country-Worst Case
    • 6.3.1. Table-Molecular Dx Total Demand by Country-Worst Case
    • 6.3.2. Table-Serology Dx Total Demand by Country-Worst Case
    • 6.3.3. Chart-Global Molecular Dx Total Demand by Quarter-Worst Case
    • 6.3.4. Chart-Global Serology Dx Total Demand by Quarter-Worst Case

Table of Tables

  • Table 1 - Who List of Potential Pandemic Pathogens
  • Table 2 - Characteristics of Coronavirus Pandemic Infections
  • Table 3 - COVID-19 Symptoms
  • Table 4 - The Three Scenarios
  • Table 5 - Test Consumption Outlook Based on Mid July Daily Run Rate - Relative Percentages per quarter
  • Table 6 - Scenario 1 Assumptions
  • Table 7 - Scenario 2 Assumptions
  • Table 8 - Scenario 3 Assumptions
  • Table 9 - Healthcare Dx Total Demand by Country - Best Case
  • Table 10 - Healthcare Dx Total Met Demand by Country - Expected Case
  • Table 11 - Healthcare Dx Total Demand by Country - Worst Case
  • Table 12 - Molecular Dx Total Demand by Country - Best Case
  • Table 13 - Molecular Dx Total Demand by Country - Expected Case
  • Table 14 - Serology Dx Total Demand by Country - Expected Case
  • Table 15 - Molecular Dx Total Demand by Country - Worst Case
  • Table 16 - Serology Dx Total Demand by Country - Worst Case

Table of Figures

  • Figure 1 - Global Distribution Pandemic Preparedness
  • Figure 2 - Global Pandemic Pathogen Status
  • Figure 3 - Estimated Economic Impact of Viral Pandemic by Region
  • Figure 4 - Historical Pandemics Infographic
  • Figure 5 - Antigenic Drift Creates a new Strain of Virus
  • Figure 6 - Structure of Coronaviruses
  • Figure 7 - 1918 Flu - 2 Infection Curves
  • Figure 8 - Global Healthcare Diagnostics Demand by Quarter - Best Case
  • Figure 9 - Global Healthcare Diagnostics Demand by Quarter - Expected Case
  • Figure 10 - Global Healthcare Diagnostics Demand by Quarter - Worst Case
  • Figure 11 - Global Healthcare Diagnostics Molecular Demand by Quarter - Best Case
  • Figure 12 - Global Healthcare Diagnostics Serology Demand by Quarter - Best Case
  • Figure 13 - Global Healthcare Diagnostics Molecular Demand by Quarter - Expected Case
  • Figure 14 - Global Healthcare Diagnostics Total Demand by Quarter - Expected Case
  • Figure 15 - Global Healthcare Diagnostics Molecular Demand by Quarter - Best Case
  • Figure 16 - Global Healthcare Diagnostics Serology Demand by Quarter - Worst Case
Back to Top